Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

Arthritis and Rheumatism

Volumn 43, Issue 5, 2000, Pages 978-987

  Cannon, Grant W ^a   Caldwell, Jacques R ^c   Holt, Peter ^c   McLean, Barry ^c   Seidenberg, Beth ^b   Bolognese, James ^b   Ehrich, Elliot ^b   Mukhopadhyay, Suarabh ^b   Daniels, Brian ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ROFECOXIB;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; SULFONES; THERAPEUTIC EQUIVALENCY;

EID: 0034041594     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0     Document Type: Article

References (48)

1. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 1997;24 Suppl 49:20-4.
2. Brandt KD. Osteoarthritis. In: Isselbacher KJ, Braunwald E, Wilson J, Martin J, Fauci A, Kasper D, editors. Harrison's principles of internal medicine. 12th ed. New York: McGraw-Hill; 1991. p. 1475-9.
3. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18 Suppl 28;6-10.
4. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
5. Richardson C, Emery P. The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Drug Saf 1996;15:249-60.
6. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
7. De Brum-Fernandes AJ. New perspectives for nonsteroidal antiinflammatory therapy. J Rheumatol 1997;24:246-8.
8. Donnelly MT, Hawkey CJ. COX-II inhibitors: a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-36.
9. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-32.
10. O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatctracnoic acid. Mol Pharmacol 1994;45:245-54.
11. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endo-peroxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
12. Meade EA, Smith WL, deWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
13. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996;111:445-54.
14. Berg J, Christoph T, Widerna M, Bodenteich A. Isoenzyme specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line mono mac 6. J Pharmacol Toxicol Methods 1997;37: 179-86.
15. Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, et al. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm Res 1997;46:51-9.
16. Miralpeix M, Camacho M, Lopez-Belmonte J, Canalias F, Beleta J, Palacios JM, et al. Selective induction of cyclo-oxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: biochemical and pharmacological characterization. Br J Pharmacol 1997;121:171-80.
17. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-8.
18. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol Suppl 1992;92:21-4.
19. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115: 787-96.
20. Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Med Inflamm 1996;5:305-23.
21. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994;4:17-23.
22. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L745.337 - a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-7.
23. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
24. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res Rev 1996;16:181-206.
25. Prasit P, Riendeau D. Selective cyclooxygenase 2 inhibitors. Annu Rep Med Chem 1997;30:179-88.
26. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
27. Ehrich E, Dallob A, van Hecken A, Depré M, DeLepeleire I, Brideau C, et al. Demonstration of selective COX-2 inhibition by MK-966 in humans [abstract]. Arthiritis Rheum 1996;39 Suppl 9:S81.
28. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effects of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
29. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
30. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
31. Bellamy N, Carette S, Ford PM, Kean WF, leRiche NGH, Lussier A, et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials - results of a consensus development (Delphi) exercise. J Rheumatol 1992;19:451-7.
32. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenae in osteoarthritis patients. Br J Rheumatol 1998;37:937-45.
33. Altman R, Asch F, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
34. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
35. The Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Fngl J Med 1988;318: 262-4.
36. Ehrich E, Schnitzer T, Kivitz A, Weaver A, Wolfe F, Morrison B, et al. MK-996, a highly selective cox-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study [abstract]. Arthritis Rheum 1997:40 Suppl 9:S85.
37. Ehrich E, Davies O, Watson W, Bolognese J, Seidenberg B, Bellamy N. Minimal perceptible clinical improvement in osteoarthritis: WOMAC and global assessments, influence of age, gender and geographic region [abstract]. Arthritis Rheum 1999;42 Suppl 9:S143.
38. Saag K, Fisher C, McKay J, Ehrich E, Zhao P-L, Bolognese J, et al, for the MK-996 Phase III Protocol 033 Study Group. MK-0966, a specific cox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial [abstract]. Arthritis Rheum 1998;41 Suppl 9:S196.
39. Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206.
40. Ward DE, Veys EM, Bowdler JM, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995;14:656-62.
41. Bellamy N, Buchanan WW, Chalmers A, Ford PM, Kean WF, Gunnar RG, et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993;20:999-1004.
42. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
43. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 (COX-2) with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13: 761-7.
44. Langman M, Jensen D, Watson DJ, Harper S, Zhao P, Bolognese J, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
45. Purcell P, Henry D, Melville G. Diclofenac hepatitis. Gut 1991; 32:1381-5.
46. Guan Y, Chang M, Cho W, Zhang Y, Redha R, Davis L, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997;273:F18-26.
47. Yang T, Singh I, Pham A, Sun D, Smart A, Schnermann J, et al. Differential response of renal cortical and inner medullary cyclooxygenase-2 (COX-2) expression to dietary salt [abstract]. J Am Soc Nephrol 1997;8:S621.
48. Catella-Lawson F, McAdam B, Morrison BW, Kapour S, Kuobu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;:289:735-41.